Therefore, PD-L1 expression, an important indicator of tumor immune resistance, has been reported to be a prognostic predictor of various carcinomas, including OSCC.[15–19] A relationship between invasive ability and PD-L1 expression in OSCC has been reported previously.[19] However, the relationship between bone invasion and PD-L1 expression in patients with OSCC, particularly LGSCC, remains unclear. This evidence concerns the gene CD274 and carcinoma.